Search alternatives:
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
161
-
162
-
163
-
164
Subgroup analysis of BUN based on pump type.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
165
Subgroup analysis of BUN based on surgery type.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
166
-
167
-
168
-
169
FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells.
Published 2019“…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD<sub>50</sub> = 8.4 μM, p ≤ 0.05). …”
-
170
-
171
-
172
-
173
-
174
-
175
Image_3_Prediction of clinically significant prostate cancer with a multimodal MRI-based radiomics nomogram.tif
Published 2022“…Objective<p>To develop and validate a multimodal MRI-based radiomics nomogram for predicting clinically significant prostate cancer (CS-PCa).…”
-
176
Table_1_Prediction of clinically significant prostate cancer with a multimodal MRI-based radiomics nomogram.docx
Published 2022“…Objective<p>To develop and validate a multimodal MRI-based radiomics nomogram for predicting clinically significant prostate cancer (CS-PCa).…”
-
177
Table_3_Prediction of clinically significant prostate cancer with a multimodal MRI-based radiomics nomogram.docx
Published 2022“…Objective<p>To develop and validate a multimodal MRI-based radiomics nomogram for predicting clinically significant prostate cancer (CS-PCa).…”
-
178
Table_2_Prediction of clinically significant prostate cancer with a multimodal MRI-based radiomics nomogram.docx
Published 2022“…Objective<p>To develop and validate a multimodal MRI-based radiomics nomogram for predicting clinically significant prostate cancer (CS-PCa).…”
-
179
Image_2_Prediction of clinically significant prostate cancer with a multimodal MRI-based radiomics nomogram.tif
Published 2022“…Objective<p>To develop and validate a multimodal MRI-based radiomics nomogram for predicting clinically significant prostate cancer (CS-PCa).…”
-
180
Image_1_Prediction of clinically significant prostate cancer with a multimodal MRI-based radiomics nomogram.tif
Published 2022“…Objective<p>To develop and validate a multimodal MRI-based radiomics nomogram for predicting clinically significant prostate cancer (CS-PCa).…”